Oncorus Raises $79.5m To Take Its First Oncolytic Virus Into The Clinic

 
• By Mandy Jackson

The company has two oncolytic virus platforms – a herpes simplex-based intratumoral injection and a synthetic virus-based intravenous technology for repeat systemic administration.

stairs to the big money - Image
Oncolytic virus developer Oncorus closed a series B round. • Source: Shutterstock

More from Financing

More from Business